Travere Therapeutics, Inc.
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients witā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$27.80
Price+0.91%
$0.25
1Y
Price
Market Cap
$2.564b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-0.5%
EBITDA Margin-16.9%
Net Profit Margin+47.1%
Free Cash Flow Margin-0.5%
EBITDA Margin-16.9%
Net Profit Margin+47.1%
Free Cash Flow MarginRevenue
$490.728m
+110.5%
1y CAGR+67.9%
3y CAGR+46.7%
5y CAGREarnings
-$50.261m
+84.4%
1y CAGR-14.8%
3y CAGR-24.7%
5y CAGREPS
-$0.56
+85.3%
1y CAGR-7.0%
3y CAGR-16.5%
5y CAGRBook Value
$114.828m
$605.191m
Assets$490.363m
Liabilities$328.733m
DebtDebt to Assets
54.3%
15.3x
Debt to EBITDAFree Cash Flow
$37.784m
+107.7%
1y CAGR+17.5%
3y CAGR-99.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company